Overview

Clinical Endpoint Study of Ivermectin 1% Cream

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.
Phase:
Phase 3
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Ivermectin